The landscape of reconstructive and aesthetic surgery is poised for a technological revolution. The American Society of Plastic Surgeons (ASPS), in partnership with the world’s leading medical technology accelerator, MedTech Innovator (MTI), has officially announced the five startups selected to headline the 2026 Plastic Surgery specialty track. These companies—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—represent the vanguard of medical innovation, chosen for their potential to redefine patient outcomes, streamline surgical precision, and integrate cutting-edge digital health solutions into the operating room.
As these startups embark on their journey through the MTI accelerator program, they enter an ecosystem designed to bridge the gap between benchtop research and bedside application. By navigating the rigorous challenges of commercialization, growth, and regulatory approval, these firms aim to secure a portion of $800,000 in non-dilutive funding, with the ultimate victors to be crowned this fall at The MedTech Conference in Boston.
The Path to Selection: A Competitive Crucible
The road to the 2026 cohort was anything but easy. This year, the ASPS-MedTech Innovator track saw a record surge in interest, with 135 early- to mid-stage startups submitting applications. These applicants represented a diverse array of medical devices, diagnostic platforms, and digital health interventions, all seeking to solve critical pain points within the field of plastic and reconstructive surgery.
The Selection Process
The vetting process was both exhaustive and collaborative. Following an initial review by industry experts and plastic surgeons, the field was narrowed to 12 semi-finalists. These companies were invited to San Francisco for a high-stakes, live-pitch judging round. During these sessions, founders were evaluated not just on the technical viability of their products, but on their business strategy, potential for scalability, and their alignment with the clinical needs of the plastic surgery community.
The five companies selected—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—distinguished themselves through a blend of disruptive technology and a clear vision for the future of patient care.
Chronology of the ASPS and MedTech Innovator Partnership
The collaboration between ASPS and MedTech Innovator is now in its fifth year, a partnership that has matured into a cornerstone of innovation for the specialty.
- 2021: The Genesis of the Track. The ASPS launched the specialty track with MedTech Innovator to identify high-potential technologies early in their development lifecycle.
- 2021–2024: A Track Record of Growth. Over the past four years, 18 companies have successfully traversed the program. These alumni have collectively raised over $120 million in funding, with two startups achieving successful exits, proving the program’s ability to identify "unicorn" potential.
- 2025–2026: Scaling the Impact. The current iteration has seen increased investment in mentorship, with a focus on providing these startups with direct access to surgeons who can provide iterative feedback on product design.
- October 2026: The Showcase. The journey will culminate at Plastic Surgery The Meeting in Houston (Oct. 15–18), where the five finalists will engage directly with the global plastic surgery community, showcasing their prototypes to the very surgeons who will eventually use them.
Supporting Data: The Power of the Accelerator Model
The impact of the MedTech Innovator program extends far beyond the ASPS partnership. Since its inception in 2013, MTI has established itself as the gold standard for medical technology acceleration.
By the Numbers:
- Global Reach: MTI has supported more than 800 startups worldwide.
- Capital Infusion: Graduates of the program have secured more than $11 billion in equity funding.
- Regulatory Success: The program has been a catalyst for more than 500 FDA approvals and authorizations, demonstrating the effectiveness of the accelerator’s mentorship in navigating the complex regulatory landscape of the United States.
- The ASPS Specialty Track Advantage: The 18 alumni of the plastic surgery-specific track have secured over $337,000 in direct prize money, in addition to the invaluable mentorship and corporate connections facilitated by the partnership.
This data underscores the reality that for a medical startup, success is rarely about the idea alone—it is about the infrastructure of support, mentorship, and validation provided by programs like MTI.
Perspectives from Leadership: A Strategic Vision
For the American Society of Plastic Surgeons, this partnership is not merely a sponsorship; it is an investment in the future of the specialty. By embedding themselves in the innovation process, plastic surgeons are ensuring that the tools of tomorrow are built to meet the realities of today’s operating room.
"Plastic surgery has always been a specialty driven by innovation, and the Society’s unique partnership with MedTech Innovator allows us to help shape the next generation of technologies," said Babak Mehrara, MD, president of The Plastic Surgery Foundation.
Dr. Mehrara emphasized the importance of the clinical feedback loop. "By connecting entrepreneurs with the expertise of plastic surgeons, we’re helping ensure these solutions are developed with patients’ needs in mind while accelerating innovations that have the potential to strengthen patient care across the specialty."
This sentiment is echoed by the leadership at MedTech Innovator. The program’s model relies on a network of 35 corporate partners and over 1,000 industry executives, including investors and business development leads. This creates a "mentorship ecosystem" where startups receive individualized guidance that is rarely available to companies at such an early stage.
Implications: How These Innovations Change Patient Outcomes
The inclusion of companies like FeminAI and GenesisTissue suggests that the future of plastic surgery is moving toward high-precision, AI-driven, and bio-integrated solutions.
1. Digital Health and AI Integration
Startups like FeminAI and ImageAssist represent the shift toward digitizing the aesthetic and reconstructive journey. From advanced imaging to AI-driven diagnostic tools, these technologies aim to reduce the "guesswork" in surgical planning, leading to more predictable patient outcomes and increased satisfaction.
2. Tissue Engineering and Advanced Materials
Companies such as GenesisTissue and GenAssist are tackling the complexities of wound healing, tissue regeneration, and scaffold integration. These technologies are critical for reconstructive surgeons, who often face the challenge of restoring function and form to patients following trauma, cancer, or congenital conditions.
3. The Future of Fixation
With Tissuelock, the focus shifts to surgical technique and hardware. Improving the way tissue is secured or held during and after surgery has long been a goal for plastic surgeons looking to minimize scarring and improve long-term structural integrity.
The Mentorship Ecosystem: A Holistic Approach to Growth
What sets the ASPS-MTI program apart from a traditional venture capital incubator is its emphasis on the "Corporate Mentorship Program." Each of the five startups is paired with senior industry executives who have successfully brought medical devices to market.
These mentors provide:
- Regulatory Guidance: Assistance in drafting the necessary documentation for FDA submissions.
- Strategic Support: Advice on market entry, reimbursement strategies, and building a sustainable business model.
- Clinical Validation: Opportunities to present to surgeons and hospital administrators, providing the startup with "real-world" feedback before a full-scale commercial launch.
As the cohort prepares for the fall competition, they will participate in a series of coaching sessions. These sessions are designed to prepare them for the rigorous demands of the investment community, ensuring that their innovations are not only clinically sound but also commercially viable.
Looking Ahead: The October Showcase in Houston
The culmination of this year’s program will occur at Plastic Surgery The Meeting in Houston. For these five startups, the conference represents the ultimate "coming out party." Attendees will have the opportunity to interact with the technologies, engage with the founders, and witness firsthand how these innovations might be integrated into their own practices.
For the plastic surgery community, this represents a unique opportunity to witness the cutting edge of the field. By fostering a direct relationship between surgeons and the engineers/entrepreneurs developing these tools, the ASPS is ensuring that the evolution of plastic surgery remains a clinician-led, patient-centered endeavor.
About MedTech Innovator
Based in Los Angeles, MedTech Innovator is the world’s largest accelerator of medical technology companies and the premier nonprofit startup accelerator in the medical technology industry. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system.
In collaboration with its partners and a broader network of stakeholders, MedTech Innovator provides startups with the resources necessary to navigate the "valley of death"—the period between product conception and commercial success. By focusing on individualized mentorship, funding opportunities, and continual engagement, MTI continues to set the standard for how the medical industry can foster innovation from the ground up.
For more information about MedTech Innovator, visit https://medtechinnovator.org/, and stay updated on the latest developments by following @MedTechAwards on X and MedTech Innovator on LinkedIn.
As the 2026 cohort continues their journey, the global medical community will be watching to see which of these five startups will secure the top prize—and, more importantly, which of these innovations will fundamentally change the standard of care for patients undergoing plastic and reconstructive procedures.
About the Author
